Atlas Capital Advisors LLC Grows Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Atlas Capital Advisors LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 8.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,797 shares of the company’s stock after buying an additional 282 shares during the quarter. Atlas Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $320,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Titan Capital Management LLC CA acquired a new stake in Merck & Co., Inc. in the second quarter valued at about $25,000. LFA Lugano Financial Advisors SA lifted its position in Merck & Co., Inc. by 250.0% in the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after purchasing an additional 225 shares during the period. JJJ Advisors Inc. acquired a new stake in Merck & Co., Inc. in the second quarter valued at about $27,000. Cumberland Partners Ltd acquired a new stake in Merck & Co., Inc. in the second quarter valued at about $40,000. Finally, Fusion Family Wealth LLC lifted its position in Merck & Co., Inc. by 268.2% in the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after purchasing an additional 354 shares during the period. 74.95% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Richard R. Deluca sold 6,427 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.27% of the stock is currently owned by company insiders.

MRK stock opened at $83.25 on Thursday. The firm has a 50 day moving average of $84.03 and a 200-day moving average of $82.67. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $87.35. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The company has a market cap of $217.48 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 1.84 and a beta of 0.54.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. The company had revenue of $12.40 billion during the quarter, compared to the consensus estimate of $11.59 billion. During the same period last year, the firm earned $1.19 EPS. The company’s revenue for the quarter was up 14.9% on a year-over-year basis. Sell-side analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on the stock. Mizuho raised their price objective on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Bank of America assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price objective for the company. Leerink Swann assumed coverage on shares of Merck & Co., Inc. in a research report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price objective for the company. Finally, Argus raised their price objective on shares of Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $95.13.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Oversold

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.